You searched for "macular"
Comparison of ganglion cell thinning in glaucoma vs. macular hole repair
1 December 2014
| Khadijah Basheer
|
Retina / Uvea / Vitreous
|
Ganglion cell complex, PhNR, glaucoma, macular hole, photopic negative response
This prospective study compared the changes in the photopic negative response of the focal macular electroretinogram (fmERG) caused by retinal ganglion cell complex (GCC) thinning at the macula between patients with open angle glaucoma (OAG) and 12 months after successful...
OCTA in diabetic macular oedema treated with intravitreal aflibercept (DOCTA Study)
3 April 2024
| Sofia Rokerya
|
Retina / Uvea / Vitreous
Central vision loss due to diabetic macular oedema (DME) can be attributed not only to presence of the macular oedema itself but also, in some cases, to alterations of the foveal avascular zone (FAZ). The DOCTA trial was a longitudinal,...
Inner nuclear layer of the retina showing increase in thickness in diabetic macular oedema
1 October 2015
| Bheemanagouda Patil
|
Retina / Uvea / Vitreous
Diabetic retinopathy is one of the leading causes of blindness in the developed world. With optical coherence tomography (OCT), it has become possible to image the retina in vivo and to measure retinal oedema by measuring retinal thickness (RT) with...
Ranibizumab versus laser in diabetic macular oedema (LUCIDATE study)
1 October 2014
| Efrosini Papagiannuli
|
Retina / Uvea / Vitreous
The aim of this study was to compare the functional and structural effects of Ranibizumab versus macular laser treatment in patients with diabetic macular oedema. It was a single centre, prospective, randomised, single masked clinical trial spanning a 48 week...
Pathophysiology of diabetic macular oedema: why combination therapy may be better
1 October 2015
| Winfried MK Amoaku
|
Retina / Uvea / Vitreous
The prevalence of diabetes has continued to increase over the years. It is currently estimated that there are 382 million with diabetes worldwide in 2013, and that this figure is expected to rise to 592 million by 2035 [1]. In...
Clinical relevance of the anatomic classification of neovascular age-related macular degeneration
The author explains why an OCT-based classification of neovascular AMD is needed and how these neovascular subtypes may help to predict patients’ long-term visual outcome. Age-related macular degeneration (AMD) is a chronic and progressive neurodegenerative process involving the macula in...Association between neurodegeneration and macular perfusion in the progression of diabetic retinopathy
9 August 2023
| Sofia Rokerya
|
Retina / Uvea / Vitreous
|
Diabetes, Neurodegeneration, Progression, Retinopathy, Vessel closure
In this prospective three-year longitudinal study, the authors aimed to explore the relation between retinal neurodegenerative changes and vessel closure (VC) in individuals with non-proliferative diabetic retinopathy (NPDR). The participants included 74 individuals with type 2 diabetes, NPDR, and Early...
Choroidal and macular thickness in nonarteritic anterior ischaemic optic neuropathy
1 December 2014
| Claire Howard
|
Neuro-Ophthalmology
|
Choroidal thickness, enhanced depth imaging, macular thickness, nonarteritic anterior ischemic optic neuropathy, optical coherence tomography
This study evaluates the choroidal and macular thickness in patients with chronic nonarteritic anterior ischaemic optic neuropathy (NA-AION). Two groups of subjects were compared, group one included 20 eyes with chronic NA-AION and group two, 31 healthy control eyes. The...
High dose (2.5mg) bevacizumab for postradiation cystoid macular oedema
1 April 2017
| Yamini Krishna
|
Ocular Pathology and Oncology
|
Anti-VEGF, Cystoid macular edema, Melanoma, Radiation damage, Radiotherapy, Tumor
The authors present a retrospective, interventional case series investigating the efficacy of high dose (2.5mg/0.1ml) intravitreal bevacizumab in the treatment of persistent postradiation (Iodine-125 plaque brachytherapy for uveal melanoma) cystoid macular oedema (CME). Persistent CME was defined as increased or...
Progression of macular atrophy on long-term anti-VEGF therapy for AMD
3 October 2022
| Sofia Rokerya
|
Retina / Uvea / Vitreous
|
Anti-VEGF therapy, Long term, Macular atrophy, neovascular age-related macular degeneration
This retrospective study evaluated the progression of macular atrophy in 53 eyes of 53 patients receiving AntiVEGF Therapy for age-related macular degeneration (nAMD), for at least six years. None of the patients had any macular atrophy (MA) at presentation. MA...
Efficacy of intravitreal dexamethasone implant in patients with persistent macular oedema
1 December 2014
| Sofia Rokerya
|
Retina / Uvea / Vitreous
Chronic cystoid macular oedema (CME) can develop secondary to various pathologies such as diabetic maculopathy, retinal vein occlusion and uveitis. It can cause significant visual impairment and macular damage. The therapeutic effect of corticosteroids in CME is through one or...
Steroid implants in the treatment of post-epiretinal membrane peel macular oedema
1 February 2018
| Kurt Spiteri Cornish
|
Retina / Uvea / Vitreous
|
Central retinal thickness, Dexamethasone implant, Fluocinolone acetonide implant, Intravitreal steroid implants, Long-term outcome, Macular pucker surgery, Membrane peeling, Pars plana vitrectomy, Persistent macular edema
This is a retrospective review of 39 eyes of 37 patients treated with Ozurdex® (intravitreal dexamethasone implant) for persistent post-operative cystoid macular oedema (CMO) following vitrectomy and idiopathic epiretinal membrane (ERM) peeling. The 0.7mg implant was injected in each eye...